In this workshop, Mark Stewart, PhD, Vice President, Science Policy at Friends of Cancer Research, discusses Friends™ efforts to standardize TMB measurements to ensure clinically-meaningful results, and SeraCare™'s contributions to the project as the sole provider of TMB reference standards to Friends™ TMB Harmonization Working Group
Harmonization of methods to quantify tumor mutational burden (TMB) will facilitate robust biomarker development and optimize clinical utilization and treatment decision-making. Friends aims to better understand the impact of assay variation on clinical outcomes, align standards, and define best practices for TMB assessment.
Offered Free by: LGC SeraCare Life Sciences
See All Resources from: LGC SeraCare Life Sciences
Thank you
This download should complete shortly. If the resource doesn't automatically download, please, click here.
Thank you
This download should complete shortly. If the resource doesn't automatically download, please, click here.
Thank you
This download should complete shortly. If the resource doesn't automatically download, please, click here.